Literature DB >> 35518791

Effectiveness of casirivimab/imdevimab in an intensive care unit patient with acute respiratory failure due to SARS-CoV-2 infection.

Benjamin Sloan1, Erin Duhaime2, Uriel Sandkovsky2, Mezgebe Berhe2.   

Abstract

Casirivimab/imdevimab, a cocktail of monoclonal antibodies, is currently approved for emergency use in high-risk ambulatory patients with early COVID-19 to reduce risk of hospitalization and/or death from SARS-CoV-2 infection. In the United States, there is no approved monoclonal antibody therapy for patients hospitalized for complications due to acute SARS-CoV-2 infection. We describe here the use of casirivimab/imdevimab in a 52-year-old fully vaccinated, immunocompromised man admitted to the intensive care unit for acute hypoxemic respiratory failure due to SARS-CoV-2 infection.
Copyright © 2022 Baylor University Medical Center.

Entities:  

Keywords:  COVID-19; Casirivimab/imdevimab; SARS-Cov-2; immunocompromised patients; monoclonal antibodies

Year:  2022        PMID： 35518791      PMCID： PMC9037465          DOI： 10.1080/08998280.2022.2042033

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN： 0899-8280


  8 in total

1.  Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial.

Authors:  Jens D Lundgren; Birgit Grund; Christina E Barkauskas; Thomas L Holland; Robert L Gottlieb; Uriel Sandkovsky; Samuel M Brown; Kirk U Knowlton; Wesley H Self; D Clark Files; Mamta K Jain; Thomas Benfield; Michael E Bowdish; Bradley G Leshnower; Jason V Baker; Jens-Ulrik Jensen; Edward M Gardner; Adit A Ginde; Estelle S Harris; Isik S Johansen; Norman Markowitz; Michael A Matthay; Lars Østergaard; Christina C Chang; Anna L Goodman; Weizhong Chang; Robin L Dewar; Norman P Gerry; Elizabeth S Higgs; Helene Highbarger; Daniel D Murray; Thomas A Murray; Ven Natarajan; Roger Paredes; Mahesh K B Parmar; Andrew N Phillips; Cavan Reilly; Adam W Rupert; Shweta Sharma; Kathryn Shaw-Saliba; Brad T Sherman; Marc Teitelbaum; Deborah Wentworth; Huyen Cao; Paul Klekotka; Abdel G Babiker; Victoria J Davey; Annetine C Gelijns; Virginia L Kan; Mark N Polizzotto; B Taylor Thompson; H Clifford Lane; James D Neaton
Journal:  Ann Intern Med       Date:  2021-12-21       Impact factor: 51.598

2.  Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.

Authors: 
Journal:  Lancet       Date:  2021-05-14       Impact factor: 79.321

3.  REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.

Authors:  David M Weinreich; Sumathi Sivapalasingam; Thomas Norton; Shazia Ali; Haitao Gao; Rafia Bhore; Bret J Musser; Yuhwen Soo; Diana Rofail; Joseph Im; Christina Perry; Cynthia Pan; Romana Hosain; Adnan Mahmood; John D Davis; Kenneth C Turner; Andrea T Hooper; Jennifer D Hamilton; Alina Baum; Christos A Kyratsous; Yunji Kim; Amanda Cook; Wendy Kampman; Anita Kohli; Yessica Sachdeva; Ximena Graber; Bari Kowal; Thomas DiCioccio; Neil Stahl; Leah Lipsich; Ned Braunstein; Gary Herman; George D Yancopoulos
Journal:  N Engl J Med       Date:  2020-12-17       Impact factor: 91.245

4.  SARS-CoV-2 late shedding may be infectious between immunocompromised hosts.

Authors:  Ville Kaila; Simo Sirkeoja; Soile Blomqvist; Juha Rannikko; Hanna Viskari; Tiina Lyly-Yrjänäinen; Jaana Syrjänen
Journal:  Infect Dis (Lond)       Date:  2021-06-17

5.  Effect of Monoclonal Antibody Treatment on Clinical Outcomes in Ambulatory Patients With Coronavirus Disease 2019.

Authors:  Blake Anderson; Zirka Smith; Srilatha Edupuganti; Xiaobo Yan; Christopher M Masi; Henry M Wu
Journal:  Open Forum Infect Dis       Date:  2021-06-12       Impact factor: 3.835

6.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Authors:  Fei Zhou; Ting Yu; Ronghui Du; Guohui Fan; Ying Liu; Zhibo Liu; Jie Xiang; Yeming Wang; Bin Song; Xiaoying Gu; Lulu Guan; Yuan Wei; Hui Li; Xudong Wu; Jiuyang Xu; Shengjin Tu; Yi Zhang; Hua Chen; Bin Cao
Journal:  Lancet       Date:  2020-03-11       Impact factor: 79.321

7.  Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial.

Authors: 
Journal:  Lancet Infect Dis       Date:  2021-12-23       Impact factor: 71.421

8.  Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19.

Authors:  Meagan P O'Brien; Eduardo Forleo-Neto; Bret J Musser; Flonza Isa; Kuo-Chen Chan; Neena Sarkar; Katharine J Bar; Ruanne V Barnabas; Dan H Barouch; Myron S Cohen; Christopher B Hurt; Dale R Burwen; Mary A Marovich; Peijie Hou; Ingeborg Heirman; John D Davis; Kenneth C Turner; Divya Ramesh; Adnan Mahmood; Andrea T Hooper; Jennifer D Hamilton; Yunji Kim; Lisa A Purcell; Alina Baum; Christos A Kyratsous; James Krainson; Richard Perez-Perez; Rizwana Mohseni; Bari Kowal; A Thomas DiCioccio; Neil Stahl; Leah Lipsich; Ned Braunstein; Gary Herman; George D Yancopoulos; David M Weinreich
Journal:  N Engl J Med       Date:  2021-08-04       Impact factor: 91.245
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.